statement
On 17 October 2026, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 anti-cancer non-scheduled medicines, including patented drugs, at 30% of the maximum retail price (MRP).
A statement by नेशनल फार्मास्युटिकल प्राइसिंग अथॉरिटी (NPPA). Statements are as reported by the cited publishers — not verified by DecisionGateway.
17 अक्टूबर 2026 को, नेशनल फार्मास्युटिकल प्राइसिंग अथॉरिटी (NPPA) ने कैंसर-रोधी 137 गैर-अनुसूचित (non-scheduled) दवाओं - जिनमें पेटेंट वाली दवाएं भी शामिल हैं - पर ट्रेड मार्जिन को अधिकतम खुदरा मूल्य (MRP) के 30% तक सीमित कर दिया है।
Discussion
Related claims
On 17 October 2026, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 non-scheduled anti-cancer medicines, including patented drugs, at 30% of the maximum retail price (MRP).post · statementOn October 17, 2026, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 non-scheduled anti-cancer medicines, including patented ones, at 30% of the maximum retail price (MRP).National Pharmaceutical Pricing Authority (NPPA) · statementOn October 17, 2026, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 non-scheduled anti-cancer medicines, including patented ones, at 30% of the maximum retail price (MRP).post author · statementAs of 4 November 2026, 70 companies had announced revised MRPs for 120 medicines.post · statementEstimated savings are ₹3,357.49 crore (as on November 4, 2026), with 70 companies reporting revised MRPs for 120 drugs.post author · statementConsumers can check drug prices on the NPPA website and the official 'Pharma Sahi Daam' mobile app.post author · statement
More claims by नेशनल फार्मास्युटिकल प्राइसिंग अथॉरिटी (NPPA)
No other claims by this actor on record.